Matthew Barcus
Stock Analyst at Chardan Capital
(2.25)
# 2,563
Out of 4,835 analysts
21
Total ratings
20.83%
Success rate
17.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $1.10 | +809.09% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $13.70 | +97.08% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.86 | +714.52% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $14.46 | +121.30% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $2.27 | +9,591.63% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.66 | +238.35% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $8.06 | -0.74% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $1.10
Upside: +809.09%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $13.70
Upside: +97.08%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.86
Upside: +714.52%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $14.46
Upside: +121.30%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $2.27
Upside: +9,591.63%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.66
Upside: +238.35%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $8.06
Upside: -0.74%